Blood Testing News
-
Showcase
10 Years of Peer-Reviewed Studies Predicting and Informing the Prognosis Profile of Autoimmune Patients
Recent journal publications are fortifying the clinically important role of the 14-3-3η blood test along the whole continuum of RA and autoimmune patient care. From RA meta-analysis data through to 14-3-3η expression in juvenile idiopathic arthritis and secondary Sjögren’s syndrome in Lupus, the importance of this protein across a spectrum of autoimmune conditions is ...
-
More than muscles: Sports nutrition evolves
Ingredients for muscle mass and post-workout recovery remain mainstays in sports nutrition, but the category is evolving and broadening. Ingredient examples are phospholipids for cognition and probiotic cultures for digestive health. “It’s very well-known that health is increasingly perceived holistically by consumers, especially younger demographics,” said Paige Wilkinson, ...
By Nuritas Ltd.
-
FPI Explores the Future of Cognitive Healthcare at the 87th China International Medical Equipment Fair (CMEF)
The 87th China International Medical Equipment Fair (CMEF) opened on 14 May at the National Convention and Exhibition Centre (Shanghai). The exhibition is a trendsetter in the global medical device industry and a "top tier" medical event, with brand representatives from more than 20 countries and regions from around the world showcasing sophisticated products spanning the entire industry chain ...
-
Daxor Corporation Announces Significant Expansion With Five Hospitals Implementing Its BVA-100 Blood Volume Diagnostic for Heart Failure Patients
Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces five new hospitals have implemented the Company’s BVA-100 blood volume diagnostic for clinical use to guide fluid management in heart failure patients during the first quarter of 2023. The addition of these hospitals contributes to the significant growth of blood volume analysis (BVA) ...
-
New Study Confirms Daxor’s BVA-100 Volume Metric Compared to CardioMEMS Pressure Metric Has Unique Clinical Utility as a Diagnostic for Heart Failure Patients
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new data validating the benefits of the Company’s BVA-100 diagnostic in optimizing individualized therapy for heart failure patients. Data were presented at the Technology Heart Failure Therapeutics Conference, which focuses on device and technology-based treatments in heart failure. ...
-
Pilot Randomized Controlled Trial Validates Daxor BVA-100 Diagnostic for Heart Failure Patients
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new pilot randomized control trial (RCT) data from Duke Heart validating the greater accuracy of the Company’s BVA-100 diagnostic in optimizing decongestion therapy for heart failure patients and pointed to a strong signal toward reducing hospital length of stay in a pilot cohort of 31 ...
-
What’s Next For The Biotech Startup Alertgy and Their Non-Invasive Glucometer
Alertgy has nearly completed the process of miniaturizing its first generation NICGM® (Non-Invasive Continuous Glucose Monitor) into a smaller form factor that will be the size of modern smart watches. By replacing commercial off-the-shelf components with custom built parts, Alertgy has been able to greatly reduce the size of its NICGM. Throughout the design process, Alertgy has aimed to ...
By Alertgy
-
Daxor Corporation Appoints Linda Cooper, Vice President Project Management
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces the appointment of Linda Cooper as Vice President of Project Management. “Linda joins Daxor with over 30 years of experience in product development and commercialization in the medical device industry. Linda’s proven track record makes her an excellent addition to the Daxor team ...
-
How Technology, Early Diagnoses Can Help Turn the Tide on Prostate Cancer Prognosis
Dr. Ali Tinazli's post at the Forbes magazine about "How Technology, Early Diagnoses Can Help Turn The Tide On Prostate Cancer Prognosis" There has never been more hope or promise in the global effort to eradicate cancer. Confidence in finding lifesaving cures is at an all-time high among medical researchers who work tirelessly for a solution. Astounding ...
-
Why Knowledge Is Power In The Treatment Of Obesity
Dr. Ali Tinazli is the CEO of lifespin.health and has 15+ years in Fortune 100 corporate strategy and entrepreneurship (SONY, HP). Obesity rates continue to climb alongside a $254.9 billion global weight loss products and services market. Supplements, smartphone weight loss apps, diet plans and exercise programs are widely available to consumers, yet the World Obesity Federation projects that 1 ...
-
Daxor Corporation Joins the Heart Failure Society of America (HFSA) as a Corporate Member
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces joining the Heart Failure Society of America (HFSA) as a corporate member to collaborate and deepen engagement with leaders in the field of heart failure. “The HFSA is the premier society focused on improving Heart Failure outcomes, a condition that more than 6 million Americans ...
-
LifeScan’s Response to the Invasion of Ukraine
For over 40 years, LifeScan’s vision has been to create a world without limits for people with diabetes and related conditions, and this remains as strong today as ever, and perhaps when our support is needed most. Therefore, we are responding to the urgent humanitarian need for diabetes health medical supplies resulting from the invasion of Ukraine. As part of our longstanding commitment ...
By LifeScan
-
Newly Published Study Proves Value and CliNewly Published Study Proves Value and Clinical Benefit of Daxor’s Blood Volume (BVA-100) Diagnostic in the Evaluationnical Benefit of Daxor’s Blood Volume (BVA-100) Diagnostic in the Evaluation of Heart Failure
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces a new study in the Journal of Cardiovascular Translational Research that examined pressure-volume profiles in heart failure patients using Daxor’s BVA-100 blood test to measure intravascular volume overload compared to a commercially available implantable pulmonary artery diastolic ...
-
Daxor Corporation Announces Closing of $2.1 million Underwritten Public Offering and Exercise of Over-Allotment Option
DAXOR CORPORATION (Nasdaq: DXR) (“Daxor”, or the “Company”), the global leader in blood volume measurement technology, today announced the closing of its previously announced underwritten public offering consisting of 210,527 shares of its common stock at a public offering price of $9.50 per share. In addition, the underwriter has partially exercised its over-allotment ...
-
Daxor Corporation Announces Pricing of $2.0 million Underwritten Public Offering
DAXOR CORPORATION (Nasdaq: DXR) (“Daxor”, or the “Company”), the global leader in blood volume measurement technology, today announced the pricing of an underwritten public offering consisting of 210,527 shares of its common stock at a public offering price of $9.50 per share. The gross proceeds to Daxor from the offering, before deducting the underwriting commissions and ...
-
Daxor Corporation Announces Launch of Proposed Underwritten Public Offering
DAXOR CORPORATION (Nasdaq: DXR) (“Daxor”, or the “Company”), the global leader in blood volume measurement technology, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares of common stock are being offered by Daxor. In addition, Daxor intends to grant the underwriter in the offering a 45-day option to ...
-
New and Encouraging Global Diabetes Market Research Shows People with Diabetes are More Motivated to Manage their Condition than Healthcare Providers May Realize
Key Research Survey Findings: 52 percent of healthcare providers agreed motivation is a major barrier to patients adhering to blood glucose monitoring compared to only 10 percent of people with diabetes who agreed motivation is a major barrier. Healthcare providers claimed they are recommending blood glucose management apps to only 25 percent of their patients, while 55% of patients who ...
By LifeScan
-
Live Webinar by MedAxiom Features Best Practices Using Daxor’s Blood Volume Analysis (BVA-100) to Improve Heart Failure Outcomes & Reduce Costs
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces Daxor’s BVA-100 diagnostic will be featured in a MedAxiom Academy webinar – Best Practices for Using Blood Volume Analysis to Reduce Heart Failure LOS, Readmissions, Mortality and Costs on November 17, 2022, at 1pm ET. This live webinar will take a deep dive into the best ...
-
DiamiR Biosciences Announces Participation in Alzheimer`s Panel at the BioFuture 2022 Conference
DiamiR, a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced that the company's management will participate in the BioFuture Conference being held on November 7-9, 2022 at the Lotte New York Palace in New York City, NY. Kira Sheinerman, Ph.D., Co-Founder and Executive Director, will be a participant in the panel discussion, "New approvals, ...
By DiamiR
-
Newly Published Study Demonstrates Significant Clinical Utility of Daxor’s Blood Volume (BVA-100) Diagnostic in the Evaluation of Heart Failure
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces a new study in the prestigious Journal of Cardiac Failure demonstrating the importance and clinical utility of Daxor’s BVA-100 blood test in heart failure (HF). The researchers showed that Daxor’s BVA-100 was able to measure intravascular volume overload in heart failure ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you